Results 161 to 170 of about 11,899,956 (387)

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Cell, 2017
Padmanee Sharma, S. Hu-Lieskovan, J. Wargo, A. Ribas   +3 more
semanticscholar   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

The impact of resistance exercise range of motion on the magnitude of upper-body post-activation performance enhancement [PDF]

, 2022
Michał Krzysztofik, Robert Trybulski, Bartosz Trąbka, Dawid Perenc, Konrad Łuszcz, Adam Zając, Dan Iulian Alexe, Tatiana Dobrescu, Cristina Elena Moraru   +8 more
openalex   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Mechanisms of cross resistance between cisplatin and bleomycin in saccharomyces cerevisiae [PDF]

, 2019
Tumor cells can simultaneously acquire resistance against a diverse group of drugs. This phenomenon is called pleotropic resistance or multidrug resistance.
Burgos-Molina, Antonio Manuel, Gil-Carmona, Luisa, Ruiz-Gomez, Miguel Jose   +2 more
core  

Roles of RcsA, an AhpD Family Protein, in Reactive Chlorine Stress Resistance and Virulence in Pseudomonas aeruginosa

, 2020
Benya Nontaleerak, Jintana Duang-nkern, Lampet Wongsaroj, Wachareeporn Trinachartvanit, Adisak Romsang, Skorn Mongkolsuk   +5 more
openalex   +2 more sources

Antibiotic resistance threats in the United States, 2019

, 2019

semanticscholar   +1 more source

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Clinical Microbiology and Infection, 2012
A. Magiorakos, A. Srinivasan, R. Carey, Y. Carmeli, M. Falagas, M. Falagas, C. Giske, S. Harbarth, J. Hindler, G. Kahlmeter, B. Olsson-liljequist, D. Paterson, L. Rice, J. Stelling, M. Struelens, A. Vatopoulos, J. Weber, D. Monnet   +17 more
semanticscholar   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source